Non-invasive Assessment of Inflammatory Markers MIP-1 Alpha and IL-6 in Saliva of Post Myocardial Infarction and Stage 4 Periodontitis Patients
NCT ID: NCT05314192
Last Updated: 2022-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
80 participants
OBSERVATIONAL
2021-03-01
2021-04-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Inflammatory Markers and Periodontal Viruses on Periodontitis Patients With CAD
NCT04172870
Evaluation of Macrophage Inflammatory Protein-1α as a Periodontal Disease Biomarker
NCT06016023
NSPT on Calprotectin and Periostin Levels
NCT05618743
Evaluation of Biomarkers Levels in Gingival Crevicular Fluid, Saliva and Serum for Different Periodontal Diseases
NCT05435131
Influence of Periodontal Treatment on Systemic Inflammatory Mediators
NCT01201746
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients included in the study were categorized into four groups: (1) group 1-healthy subjects, (2) group 2-stage 4 periodontitis patients, (3) group 3- post-MI patients with stage 4 periodontitis, (4) group 4- post-MI patients without periodontitis.
The severity of the periodontitis was assessed by a periodontist. The diagnosis of acute MI was made by the cardiologists. Oral health assessment in acute MI patients was done at the subjects' bedside after stabilization of the patient, so as not to interfere with the ongoing medical treatment. Subjects' identification was kept confidential.
All samples were collected from patients admitted within 48 hours of their cardiac event. Patients were diagnosed as acute ST-elevation myocardial infarction (STEMI) based on the elevation of ST segments on the electrocardiogram(ECG) by 0.1mV in contiguous leads in patients with signs and symptoms of myocardial ischemia and/ or development of new left bundle branch block, along with increased cardiac biomarkers. Non-ST-elevation myocardial infarction (NSTEMI) was diagnosed in patients with signs and symptoms of myocardial ischemia and depression in ST-segment on the ECG or new Q wave pathology along with elevation of cardiac biomarkers.\[8\] Stage four periodontitis was diagnosed using the World Workshop 2017 classification.\[9\] Subjects who had undergone oral prophylaxis or periodontal surgery in the past 6 months were not included in the study. Smokers, pregnant women, lactating mothers, and those on medication (anti-microbial, non-steroidal anti-inflammatory drugs) in the past 3 months as well as those with other chronic systemic diseases were excluded from the study. These were all excluded as each would affect the levels of biomarkers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy
Healthy cohorts with no underlying systemic or periodontal disease
salivary test
saliva was assessed for MIP-1 alpha
salivary test
saliva was assessed for IL-6
stage 2 periodontitis
patients with periodontitis but no underlying systemic periodontal disease
salivary test
saliva was assessed for MIP-1 alpha
salivary test
saliva was assessed for IL-6
MI patients with stage 4 periodontitis
patients who had MI and having stage 4 periodontitis patients
salivary test
saliva was assessed for MIP-1 alpha
salivary test
saliva was assessed for IL-6
MI patients without periodontitis
patients who had MI without periodontitis
salivary test
saliva was assessed for MIP-1 alpha
salivary test
saliva was assessed for IL-6
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
salivary test
saliva was assessed for MIP-1 alpha
salivary test
saliva was assessed for IL-6
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* who had stage 4 periodontal disease
Exclusion Criteria
* subjects who had systemic disease other than MI
* subjects who had medication in the past 3 months
* smokers
* pregnant and lactating women
20 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
A B Shetty Memorial Institute of Dental Science
OTHER
Ajman University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
sudhir rama varma
Clinical Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AB shetty Institute of dental sciences
Mangalore, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ABSM/EC/29/2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.